Polymorphism of glutathione S-transferase in the population of Polish patients with carcinoma of the prostate

Joanna M Drozdz-Afelt,Piotr Kaminski,Grzegorz Klosowski,Beata Koim-Puchowska

doi:10.1007/s11356-020-08435-7

Abstract

The aim of the study was frequency analysis of GSTM1, GSTT1, and GSTP1 polymorphisms of glutathione S-transferase in the group of patients with prostate cancer and in a control group of healthy individuals. Genomic DNA was isolated; molecular analysis of glutathione S-transferase M1 and T2 polymorphisms was performed using multiplex PCR and RFLP methods. The products of the PCR reaction were then visualized in agarose gel, and a statistical analysis of the results was performed. No statistically significant differences were found in the frequency of glutathione S-transferase polymorphisms between 66 patients with prostate cancer and the control group (64 healthy volunteers). The GSTM1 gene deletion was found in ca. 47% of patients with prostate cancer and in ca. 55% of the controls. The GSTT1 deletion was found in approximately 17% of patients and 14% of the controls. The distribution of GSTP1 Ile/Ile, Ile/Val, and Val/Val polymorphisms was ca. 51.5%, 39%, and 9% in the group of patients and 61%, 34%, and 5% in the control group, respectively. The results indicate that there is no relationship between glutathione S-transferase polymorphisms and prostate cancer in the study group, which is a novelty when compared with the previous work on the role of these genetic variants in the etiology of cancer.

Highlights

Over the last three decades, the incidence of malignant tumors has increased dramatically
The results of molecular analysis of glutathione S-transferase polymorphisms were obtained in the form of digital images of electrophoretic gels for polymorphisms GSTM1 and GSTT1 (Fig. 1) and separately for the GSTP1 polymorphism (Fig. 2)
Glutathione S-transferases are superfamily of enzymes of the second phase of xenobiotic metabolism that play an important role in the genetics of prostate cancer

Summary

Introduction

Over the last three decades, the incidence of malignant tumors has increased dramatically. Cancers are the second leading cause of death. They are characterized by increasing incidence rate, ca. 1.96% on an annual basis in men in Poland (Didkowska et al 2009; Wojtys et al 2013; Didkowska and Wojciechowska 2015; Osowiecka et al 2019). Until the 1980, the incidence rate was dramatically increasing. After the introduction of screening for prostate-specific antigen (PSA), the incidence rate of prostate cancer stopped rising, remaining at a stable level (Kral et al 2011; Osowiecka et al 2019)

Objectives

Methods

Results

Conclusion